The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ Pasatru for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder that causes abnormal bone growth. The approval marks the first FDA-approved therapy for the condition.
Further details regarding the drug’s availability, pricing, or clinical trial outcomes were not immediately available.
